How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/myocardial-perfusion-imaging-adjunct.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Myocardial Perfusion Imaging Adjunct — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myocardial Perfusion Imaging Adjunct (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myocardial Perfusion Imaging Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cytovene	GANCICLOVIR	Roche Palo	Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor	Metabotropic glutamate receptor 1	1989-01-01
Adenocard	ADENOSINE	Astellas Pharma	Adenosine Receptor Agonist [EPC]	Adenosine receptor A3	1989-01-01
Persantine	DIPYRIDAMOLE	Boehringer Ingelheim	Platelet Aggregation Inhibitor [EPC]	Equilibrative nucleoside transporter 1	1961-01-01
Lexiscan	Lexiscan	Medical University of South Carolina		Adenosine receptor A3, Adenosine receptor A1, Adenosine receptor A2a
Adenosin	Adenosin	University of Roma La Sapienza		Phosphatidylinositol 4-kinase type 2-alpha, Phosphatidylinositol 4-kinase type 2-beta, Adenosine kinase
Regadenoson	Regadenoson	Pfizer Inc.	Adenosine receptor agonist	A2A adenosine receptor
Persantin	Persantin	Boehringer Ingelheim		Equilibrative nucleoside transporter 4, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Boehringer Ingelheim · 2 drugs in Myocardial Perfusion Imaging Adjunct
Astellas Pharma · 1 drug in Myocardial Perfusion Imaging Adjunct
Medical University of South Carolina · 1 drug in Myocardial Perfusion Imaging Adjunct
Pfizer Inc. · 1 drug in Myocardial Perfusion Imaging Adjunct
Roche Palo · 1 drug in Myocardial Perfusion Imaging Adjunct
University of Roma La Sapienza · 1 drug in Myocardial Perfusion Imaging Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myocardial Perfusion Imaging Adjunct:

Cite this brief

Drug Landscape (2026). Myocardial Perfusion Imaging Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myocardial-perfusion-imaging-adjunct. Accessed 2026-06-10.

Myocardial Perfusion Imaging Adjunct full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing